ACU Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Expansion

• Acme United reported Q2 2026 EPS of $1.22, significantly beating the $0.81 estimate, driven by a 16% year-over-year sales increase.
• Revenue reached $62.7 million, surpassing forecasts, with gross margins expanding to 42.6% from 41.0% in the prior year period.
• The primary growth driver was the January 2026 acquisition of MyMedic assets, which contributed $4.3 million in revenue during the quarter.
• Management expects continued margin recovery as lower-cost inventory replaces higher-tariff stock, though elevated SG&A expenses remain a risk.

Acme United Corporation (ACU) delivered robust second-quarter 2026 financial results that significantly exceeded Wall Street expectations. The company reported earnings per share (EPS) of $1.22, representing a substantial 50.62% surprise over the consensus estimate of $0.81. This strong performance was mirrored in top-line revenue, which reached $62.7 million against a forecast of $58.1 million, marking a 7.99% positive surprise.

The market reacted decisively to the data, with ACU shares surging approximately 11.92% to 17.52% following the report. This price movement pushed the stock near its 52-week high of $51.88, reflecting investor confidence in the company's turnaround strategy and operational efficiency.

The primary catalyst for this outperformance was the acquisition of MyMedic assets, completed on January 15, 2026, for a total purchase price of $18.5 million. This strategic move was designed to expand Acme United's product portfolio within the medical device sector, specifically targeting the emergency medical market.

The financial integration of MyMedic has already yielded tangible results. During the second quarter, the acquired assets generated $4.3 million in revenue, providing immediate top-line contribution. This acquisition contributed to a 16% year-over-year sales increase across the company.

Excluding the impact of the MyMedic acquisition, Acme United demonstrated solid organic growth, with sales increasing by 8%. This indicates that the company's core business segments are performing well independently of the new addition, suggesting a healthy underlying operational base.

How Did Acme United Improve Profitability Metrics?

Profitability metrics improved notably during the quarter, with gross margins expanding to 42.6% from 41.0% in the prior year period. This expansion indicates improved operational efficiency and effective cost management strategies implemented by the company.

Management provided optimistic guidance regarding future profitability, citing easing tariff pressures as a key driver for continued margin recovery. CEO Johnsen highlighted that the company is actively transitioning from higher-tariff inventory to lower-cost stock throughout the remainder of the year.

This inventory mix improvement is expected to further boost margins as the year progresses. The company anticipates strong fourth-quarter profitability driven by seasonal demand, which typically benefits the emergency medical device market.

The integration of MyMedic is progressing smoothly, with strategic efforts focused on expanding distribution channels. The company aims to move beyond its direct-to-consumer model and penetrate mass retail markets, leveraging MyMedic's established presence.

What Risks Should Investors Monitor in the Near Term?

Despite the positive results, investors should monitor several potential risks that could impact future performance. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, which could weigh on net profitability if not managed effectively.

The company continues to face headwinds from external factors such as tariffs, freight costs, and currency fluctuations. These costs can be volatile and may erode the gross margin improvements observed in the second quarter.

Geographic performance remains uneven, with the Canadian market currently lagging behind other regions. This disparity suggests that the company's growth is not yet uniform across all its operational territories.

While the MyMedic acquisition has provided a significant boost, the long-term return on the $18.5 million investment will depend on successful integration and sustained growth in the new segment. Investors should track quarterly reports to assess whether the acquisition continues to drive value beyond the initial integration phase.

The company's ability to navigate tariff pressures and maintain margin expansion will be critical in the coming quarters. If the transition to lower-cost inventory proceeds as planned, Acme United may continue to see improved profitability metrics.

However, the elevated SG&A expenses and potential for increased freight costs remain areas of concern. Management will need to balance growth investments with cost control to ensure sustainable earnings growth.

The focus on expanding MyMedic's distribution into mass retail represents a key strategic initiative that could unlock further growth. Success in this area would diversify revenue streams and reduce reliance on direct-to-consumer channels.

Overall, Acme United's second-quarter performance demonstrates a successful execution of its strategic acquisition and margin expansion plans. The company appears well-positioned for continued growth, provided it can effectively manage the identified risks and operational challenges.